Literature DB >> 1395090

Plasma concentration of IL-6 in systemic lupus erythematosus; an indicator of disease activity?

P E Spronk1, E J ter Borg, P C Limburg, C G Kallenberg.   

Abstract

To investigate the possible role of IL-6 in the activation of the autoimmune process in systemic lupus erythematosus (SLE), we serially measured concentrations of IL-6, IgG, and anti-dsDNA antibodies before and during exacerbations in patients with SLE. In addition, we serially related the IL-6 response to the generation of the acute phase reactant C-reactive protein (CRP). Sixteen consecutive patients who developed an exacerbation were analysed in this study. Blood samples were drawn in EDTA monthly. At the time of maximal disease activity during exacerbation, IL-6 plasma concentrations were increased (greater than or equal to 6 pg/ml) in 12 out of the 16 cases. Concentrations of IL-6 correlated with the concentrations of CRP (P less than 0.01) and the score of the disease activity index (P less than 0.05). No correlation was found between IL-6 concentrations and concentrations of anti-dsDNA or IgG. The course of changes in IL-6 concentrations before the exacerbation was variable. Five out of the 16 exacerbations studied were characterized by a prominent rise of IL-6 at the time of maximum disease activity. In this subgroup serositis as well as elevated concentrations of CRP were observed more frequently (P less than 0.02). Seven exacerbations were not accompanied or preceded by changes in IL-6 concentrations and showed generally low IL-6 concentrations. In this latter subgroup cerebral involvement was seen more frequently (P less than 0.02). Our data do not suggest a pathogenic role for IL-6 in the generation of IgG and/or anti-dsDNA antibodies before exacerbations. Rises of IL-6 concentrations before exacerbations in SLE seem only to occur in a subgroup of patients with SLE characterized by the presence of serositis and elevated concentrations of CRP during exacerbation.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1395090      PMCID: PMC1554549          DOI: 10.1111/j.1365-2249.1992.tb05840.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  14 in total

1.  Patients with systemic lupus erythematosus and Jaccoud's arthropathy: a clinical subset with an increased C reactive protein response?

Authors:  P E Spronk; E J ter Borg; C G Kallenberg
Journal:  Ann Rheum Dis       Date:  1992-03       Impact factor: 19.103

2.  Cross-linking Fc receptors on monocytes triggers IL-6 production. Role in anti-CD3-induced T cell activation.

Authors:  J Krutmann; R Kirnbauer; A Köck; T Schwarz; E Schöpf; L T May; P B Sehgal; T A Luger
Journal:  J Immunol       Date:  1990-09-01       Impact factor: 5.422

3.  Elevated levels of endogenous IL-6 in systemic lupus erythematosus. A putative role in pathogenesis.

Authors:  M Linker-Israeli; R J Deans; D J Wallace; J Prehn; T Ozeri-Chen; J R Klinenberg
Journal:  J Immunol       Date:  1991-07-01       Impact factor: 5.422

Review 4.  C-reactive protein in SLE.

Authors:  M B Pepys; J G Lanham; F C De Beer
Journal:  Clin Rheum Dis       Date:  1982-04

5.  Interleukin-6 (IL-6) and acute phase proteins in the disease course of patients with systemic lupus erythematosus.

Authors:  A J Swaak; A van Rooyen; L A Aarden
Journal:  Rheumatol Int       Date:  1989       Impact factor: 2.631

6.  Sensitive ELISA for interleukin-6. Detection of IL-6 in biological fluids: synovial fluids and sera.

Authors:  M Helle; L Boeije; E de Groot; A de Vos; L Aarden
Journal:  J Immunol Methods       Date:  1991-04-08       Impact factor: 2.303

7.  Age-dependent responsiveness to interleukin-6 in B lymphocytes from a systemic lupus erythematosus-prone (NZB x NZW)F1 hybrid.

Authors:  M E Alarcón-Riquelme; G Möller; C Fernández
Journal:  Clin Immunol Immunopathol       Date:  1992-03

8.  Measurement of increases in anti-double-stranded DNA antibody levels as a predictor of disease exacerbation in systemic lupus erythematosus. A long-term, prospective study.

Authors:  E J ter Borg; G Horst; E J Hummel; P C Limburg; C G Kallenberg
Journal:  Arthritis Rheum       Date:  1990-05

9.  Infection with HIV is associated with elevated IL-6 levels and production.

Authors:  E C Breen; A R Rezai; K Nakajima; G N Beall; R T Mitsuyasu; T Hirano; T Kishimoto; O Martinez-Maza
Journal:  J Immunol       Date:  1990-01-15       Impact factor: 5.422

10.  In vitro regulation of B cell differentiation by interleukin-6 and soluble CD23 in systemic lupus erythematosus B cell subpopulations and antigen-induced normal B cells.

Authors:  D J Klashman; R A Martin; O Martínez-Maza; R H Stevens
Journal:  Arthritis Rheum       Date:  1991-03
View more
  29 in total

Review 1.  Interleukin 6 and cognitive dysfunction.

Authors:  Isabel Trapero; Omar Cauli
Journal:  Metab Brain Dis       Date:  2014-04-30       Impact factor: 3.584

Review 2.  B lymphocyte stimulator protein levels in systemic lupus erythematosus and other diseases.

Authors:  William Stohl
Journal:  Curr Rheumatol Rep       Date:  2002-08       Impact factor: 4.592

3.  Higher level of IL-6 in Jaccoud's arthropathy secondary to systemic lupus erythematosus: a perspective for its treatment?

Authors:  Ajax Mercês Atta; Rodrigo C Oliveira; Isabela S Oliveira; Mariana P Menezes; Taciana P S Santos; Maria Luiza B Sousa Atta; Mittermayer B Santiago
Journal:  Rheumatol Int       Date:  2014-06-18       Impact factor: 2.631

4.  B cell activation in clinically quiescent systemic lupus erythematosus (SLE) is related to immunoglobulin levels, but not to levels of anti-dsDNA, nor to concurrent T cell activation.

Authors:  P E Spronk; B T vd Gun; P C Limburg; C G Kallenberg
Journal:  Clin Exp Immunol       Date:  1993-07       Impact factor: 4.330

5.  Immune function of patients receiving recombinant human interleukin-6 (IL-6) in a phase I clinical study: induction of C-reactive protein and IgE and inhibition of natural killer and lymphokine-activated killer cell activity.

Authors:  C Scheid; R Young; R McDermott; L Fitzsimmons; J H Scarffe; P L Stern
Journal:  Cancer Immunol Immunother       Date:  1994-02       Impact factor: 6.968

6.  Changes in levels of soluble T-cell activation markers, sIL-2R, sCD4 and sCD8, in relation to disease exacerbations in patients with systemic lupus erythematosus: a prospective study.

Authors:  P E Spronk; E J ter Borg; M G Huitema; P C Limburg; C G Kallenberg
Journal:  Ann Rheum Dis       Date:  1994-04       Impact factor: 19.103

Review 7.  Accelerated atherosclerosis in systemic lupus erythematosus: role of proinflammatory cytokines and therapeutic approaches.

Authors:  Chary López-Pedrera; Maria Ángeles Aguirre; Nuria Barbarroja; Maria José Cuadrado
Journal:  J Biomed Biotechnol       Date:  2010-09-26

8.  Interleukin 6 promotes murine lupus in NZB/NZW F1 mice.

Authors:  B K Finck; B Chan; D Wofsy
Journal:  J Clin Invest       Date:  1994-08       Impact factor: 14.808

Review 9.  Cytokines in systemic lupus erythematosus.

Authors:  Elaine V Lourenço; Antonio La Cava
Journal:  Curr Mol Med       Date:  2009-04       Impact factor: 2.222

10.  Serum amyloid P component levels are not decreased in patients with systemic lupus erythematosus and do not rise during an acute phase reaction.

Authors:  M Bijl; H Bootsma; Y Van Der Geld; P C Limburg; C G M Kallenberg; M H Van Rijswijk
Journal:  Ann Rheum Dis       Date:  2004-07       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.